IM047-001 A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis with an Inade

NCT05076175

A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis with an Inadequate Response to Conventional Therapy

Principal Investigator

Sponsor

Bristol-Myers Squibb Company

You are being asked to take part in this study because you have been diagnosed with or have symptoms of moderately to severely active ulcerative colitis (UC). UC is a chronic inflammatory disorder of the bowels. People with UC may suffer from diarrhea, rectal bleeding, weight loss, abdominal pain, and fever.

This study is currently enrolling.